Specifically, in several cancers including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), lower grade glioma (LGG), and uterine corpus endometrial carcinoma (UCS), the expression of FCRLB was negatively correlated with the certain TILs, immunostimulators, and immunoinhibitors markers. Here, FCRLB is linked to bladder transitional cell carcinoma.